检索结果-南通市图书馆

Expert consensus on the clinical application of pi3k/akt/mtor inhibitors in the treatment of advanced breast cancer

Cancer Innovation 2022年第1期1卷 25-54页

作者： The Society of Clinical Research of Oncology Medications of China Anticancer Association Breast Cancer Expert Committee of National Cancer Quality Control Center Boao Cancer Innovation Institute Fei Ma Binghe Xu 不详 Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/CancerHospitalChinese Academy of MedicalSciences and Peking Union MedicalCollegeBejing 100021China Department of Medical Oncology and Clinical Trial Center National Cancer Center/National ClinicalResearch Center for Cancer/CancerHospitalChinese Academy of MedicalSciences and Peking Union MedicalCollegeBeijing 100021China

Phosphoinositide 3‐kinase(pi3k)/protein kinase B(PkB or akt)/mammalian target of rapamycin(mtor)signaling pathway(PAM pathway)plays an important role in the development of breast cancer and are closely associated with the resistance to endocrine therapy in advanced breast ***,anticancer treatment targeting key molecules in this signaling pathway has become a research hotspot in recent *** clinical trials have demonstrated that pi3k/akt/mtor inhibitors bring significant clinical benefit to patients with advanced breast cancer,especially to those with hormone receptor(HR)‐positive,human epidermal growth factor receptor(HER)2‐negative advanced breast ***,a pi3k inhibitor,and everolimus,an mtor inhibitor,have been approved by *** on their high efficacy and relatively good safety profile,an expanded indication of everolimus in breast cancer has been approved by National Medical Products Administration(NMPA).Alpelisib is expected to be approved in China in the near *** members of the consensus expert panel reached this consensus to comprehensively define the role of pi3k/akt/mtor signaling pathway in breast cancer,efficacy and clinical applications of pi3k/akt/mtor inhibitors,management of adverse reactions,and pik3CA mutation detection,to promote the understanding of pi3k/akt/mtor inhibitors for Chinese oncologists,improve clinical decision‐making,and prolong the survival of target patient population.

关键词： breast cancer pi3k/akt/mtor inhibitors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：